Globally, cancer is the most common cause of mortality among all deadly diseases. As a result, a nanotechnology-based drug delivery system is used to improve the efficacy of cancer treatment, which provides an improved therapeutic index and delivers multiple drugs directly to the tumor site. In the present work, DFT calculations were employed to investigate the surface adsorption of a hydroxyurea (HU) anticancer drug on pristine graphene (GP), boron nitride (BN), and doped GP by replacing some of its carbon atoms with boron (B) and nitrogen (N) atoms to form CBN, CBN, and CBN nanosheets. In gas media, HU is adsorbed on these CBN, CBN, CBN, and BN nanosheets with adsorption energies of -0.70, -3.03, -2.47, and -1.96 eV, respectively. Alternatively, in water solvent media, the adsorption energies of CBN, CBN, CBN, and BN are -0.82, -0.29, -0.15, and -0.26 eV, respectively. The energy gaps of the nanosheets were found to be 0.288, 0.174, 0.14, and 4.562 eV before adsorption, respectively. After the adsorption of HU on the proposed nanosheets, the energy gap was reduced to 0.15 eV for CBN. According to the DOS spectra, noticeable peaks appeared in the Fermi level after the adsorption of HU on the nanosheets, which indicates the reduction of the energy gap. Quantum molecular analysis predicted that the chemical potential, electrophilicity index, and nucleophilicity index of CBN increased, whereas global hardness decreased, indicating high reactivity. Therefore, it can be concluded that among the proposed nanosheets, CBN would be an appropriate carrier for the HU drug.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322902 | PMC |
http://dx.doi.org/10.1039/d4na00428k | DOI Listing |
Fundam Res
November 2024
State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China.
The approval of Epidiolex, an anti-epileptic drug containing cannabidiol (CBD) as its active component, has brought hope to patients with refractory epilepsy. However, the anti-seizure effect of full-spectrum hemp extract (HE), a CBD-enriched hemp oil, remains unclear. In this study, we investigated the anti-seizure effect of HE using drug-induced seizure models.
View Article and Find Full Text PDFPharmacy (Basel)
December 2024
Faculty of Veterinary Medicine-Skopje, University "Ss. Cyril and Methodius", Lazar Pop-Trajkov 5/7, 1000 Skopje, North Macedonia.
The study highlights the need for quality control in evaluating medicinal plant products, especially CBD oils, before market release. Due to varying regulatory requirements, product labeling can sometimes be misleading, especially regarding cannabinoid concentrations such as CBD and THC. This research focused on developing a validated high-performance liquid chromatography (HPLC) method for accurately identifying and quantifying key cannabinoids in Commercial Veterinary CBD Oil.
View Article and Find Full Text PDFBasic Clin Pharmacol Toxicol
January 2025
Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
The worldwide legalization of medicinal cannabis has led to an increased use of products made by commercial operators. These products often contain minor cannabinoids such as cannabinol (CBN) which are advertised to improve sleep. Products are also available in which CBN is combined with conventional therapies, with a common product containing both CBN and the widely used sleep-aid melatonin.
View Article and Find Full Text PDFMed Cannabis Cannabinoids
November 2024
Faculty of Nursing, Khon Kaen University, Khon Kaen, Thailand.
Introduction: Diabetic peripheral neuropathy (DPN) represents a prevalent neurological complication affecting millions of patients globally. This clinical investigation evaluated the therapeutic efficacy and safety profile of a novel transdermal medical cannabis formulation (THC:CBD:CBN) in treating painful DPN of the lower extremities.
Methods: This phase III, double-blind, placebo-controlled, randomized clinical trial was conducted at Don Chan Hospital, Thailand, enrolling 100 participants over a 12-week intervention period.
BMC Gastroenterol
December 2024
Department of Gastroenterology and Hepatology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 14, Katowice, 40-752, Poland.
Background: Pharmacologic prophylaxis for gastric ulcer is commonly prescribed in patients hospitalized in the intensive care unit (ICU). The aim of the study was to assess the current prevalence and risk factors for gastric mucosa lesion in ICU patients receiving standard pharmacologic prophylaxis undergoing endoscopy for percutaneous gastrostomy implantation.
Methods: Patients hospitalized in the mixed medical-surgical ICU undergoing percutaneous endoscopic gastrostomy (PEG) were analyzed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!